EVALUATION OF THE SAFETY AND EFFICACY OF MEFLOQUINE AS INTERMITTENT PREVENTIVE TREATMENT FOR MALARIA IN PREGNANCY IN HIV+ PATIENTS
- Conditions
- HIV/AIDSMalariaPregnancy and Childbirth
- Registration Number
- PACTR2010020001813440
- Lead Sponsor
- FCRB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Female
- Target Recruitment
- 0
Trial 2:
Permanent resident in the area.
Gestational age at the first antenatal visit < 28 weeks
HIV seropositive (after voluntary counseling and testing)
Indication to receive CTX prophylaxis (according to the national guidelines)
Signed informed consent
Agreement to deliver in the study site's maternity wards
Trial 2:
Residence outside the study area or planning to move out in the following 10 months from enrollment
Gestational age at the first antenatal visit > 28 weeks of pregnancy
Known history of allergy to CTX or MQ
Known history of severe renal, hepatic, psychiatric or neurological disease
MQ or halofantrine treatment in the preceding 4 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.